Medical Imaging

Physicians utilize medical imaging to see inside the body to diagnose and treat patients. This includes computed tomography (CT), magnetic resonance imaging (MRI), X-ray, ultrasound, fluoroscopy, angiography,  and the nuclear imaging modalities of PET and SPECT. 

MaineHealth aims to achieve American Society of Nuclear Cardiology (ASNC) guidelines with UltraSPECT technology

Healthcare system selects UltraSPECT nuclear medicine software for lowering dose and reducing exam time.

August 29, 2013

Exploring the M.O. of drug-resistant cancers

Researchers are forever seeking to outsmart therapy-resistant cancers. "No Through Road," a feature published Aug. 5 in Cancer Today, a publication of the American Association for Cancer Research, highlights just this quest.

August 27, 2013

Siemens Healthcare introduces continuous FlowMotion PET-CT

Siemens Healthcare has launched its new Biograph mCT Flow – a groundbreaking PET-CT system. For the first time ever the system overcomes the limitations of conventional bed-based PET-CT with FlowMotion, an innovative new technology that moves the patient smoothly through the system’s gantry, while continuously acquiring PET data.

August 22, 2013

Navidea awarded NIH SBIR grant for NAV4694 beta-amyloid imaging agent phase III clinical program aimed at Alzheimer’s disease

Navidea Biopharmaceuticals announces award of a Small Business Innovation Research (SBIR) grant from the National Institute On Aging (NIA) of the National Institutes of Health (NIH) in connection with the Company's Phase 3 clinical program for its NAV4694 beta-amyloid imaging agent as an aid in the differential diagnosis of Alzheimer’s disease.

August 22, 2013

Navidea Biopharmaceuticals signs manufacturing agreement with Siemens’ PETNET Solutions for NAV4694 beta-amyloid imaging agent

Navidea has signed an agreement with Siemens’ PETNET Solutions that grants PETNET Solutions the right to manufacture Navidea’s Fluorine-18 labeled NAV4694, an investigational beta-amyloid PET imaging agent, which is currently being evaluated in Phase 2 and 3 clinical trials evaluating subjects with signs or symptoms of cognitive impairment such as Mild Cognitive Impairment and Alzheimer’s disease.

August 22, 2013

RadNet Joins Partnership to Explore Potential Alzheimer's Disease Drug

RadNet Inc. (Nasdaq:RDNT), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 248 subsidiary-owned and/or operated outpatient imaging centers, announced its participation in a clinical trial to evaluate the biomarker effects of the investigational drug E2609, a BACE inhibitor, which is being developed for the potential disease modifying treatment of Alzheimer's disease (AD).

July 16, 2013

HHS Releases 2013 Update To The National Alzheimer's Plan

Today, the Department of Health and Human Services (HHS) released the National Plan to Address Alzheimer's Disease: 2013 Update. The first-ever National Alzheimer's Plan, initially released in May 2012, was mandated by the bipartisan National Alzheimer's Project Act (P.L. 111-375), which Congress passed unanimously in 2010. The 2013 Update includes a new timeline for achieving its first goal – prevent and effectively treat Alzheimer's disease by 2025 – and a review of progress over the past year.

June 17, 2013

IBA Molecular, MIM Software Sign Agreement for PETLinQ Enhancement

IBA Molecular North America, Inc. (IBA Molecular) and MIM Software Inc. (MIM Software™) have announced an agreement to co-develop enhancements to the IBA Molecular PETLinQ™ suite of products.

June 12, 2013